Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2014', provides an overview of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview 6 Therapeutics Development 7 Pipeline Products for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview 7 Pipeline Products for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis 8 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Development by Companies 9 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Development by Companies 14 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development 15 Alkeus Pharmaceuticals, Inc. 15 Biovista Inc. 16 GenSight Biologics 17 Santhera Pharmaceuticals Holding AG 18 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 BVA-202 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 BVA-203 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Drug for Lebers Hereditary Optic Neuropathy - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 GS-010 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 idebenone - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Recent Pipeline Updates 32 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects 36 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones 37 Featured News & Press Releases 37 Jun 05, 2014: European Medicines Agency Validates Santhera's Marketing Authorization Application for Raxone in Leber's Hereditary Optic Neuropathy 37 May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON 38 Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy 38 Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France 40 Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application For Raxone In LHON 40 Jan 18, 2013: Santhera Pharma Receives Negative Opinion From EMA's CHMP On Marketing Authorization Application For Raxone 41 Nov 16, 2012: Santhera Pharma Expects CHMP Opinion On MAA For Raxone In Early 2013 42 Jul 26, 2011: Catena Improves Sight For Patients With Inherited Blindness, Newcastle University Study Finds 42 Jul 22, 2011: EMA Accepts Santhera's Marketing Authorization Application Of Idebenone For Review In LHON 43 Jun 06, 2011: Santhera Pharma Presents Nonclinical Data In LHON At Joint Congress Of SOE/AAO 2011 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2014 7 Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Comparative Analysis by Unknown Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2014 15 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc., H2 2014 16 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics, H2 2014 17 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics - Recent Pipeline Updates, H2 2014 32 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H2 2014 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
